Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematological Malignancies
Haematology
Head and Neck Cancer
Immunotherapy
Leukaemia
Lung Cancer
Lymphoma
Multiple Myeloma
Endocrine Cancers
Ovarian Cancer
Pancreatic Cancer
Paediatric Oncology
Policy
Prostate Cancer
Renal Cancer
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Neuro-oncology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic

Breast Cancer
29 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer

Diana Zhang, Amira Ishag-Osman, Chiara Corti

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

touchREVIEWS in Oncology & Haematology. 2024;20(2):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Global Forum on GU Oncology (RENALC-BLADDR-PROSCA 2024)

Global Forum on GU Oncology (RENALC-BLADDR-PROSCA 2024)
Web Address: Hybrid Global Forum on GU Oncology Website

RENALC’24, BLADDR’24 and PROSCA’24: 3 multidisciplinary, international meetings with a focus on the implications of new clinical findings on your daily practice.

When?

RENALC: 26 (PM) November 2024
BLADDR: 27 (full day) & 28 (AM) November 2024
PROSCA: 29 (full day) & 30 (AM) November 2024

Further Resources

  1. Hybrid Global Forum on GU Oncology
Breast Cancer

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer

Diana Zhang, Amira Ishag-Osman, Chiara Corti

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Advertisement

    • Latest articles videos and clinical updates - straight to your inbox

    This Functionality is for
    Members Only

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    Close Popup